Results 11 to 20 of about 7,763 (148)
Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma
Frontiers in Oncology, 2023 BackgroundDespite significant therapeutic advances over the last decade, multiple myeloma remains an incurable disease. Pomalidomide is the third Immunomodulatory drug that is commonly used to treat patients with relapsed/refractory multiple myeloma ...
Yan Zhuang +7 more
doaj +1 more source
HemaSphere, 2022 This phase 2 trial investigated reinduction with carfilzomib, pomalidomide, and dexamethasone (KPd) and continuous pomalidomide/dexamethasone in patients at first progression during lenalidomide maintenance. The second objective was to evaluate high-dose
Pieter Sonneveld +18 more
doaj +1 more source
PLoS ONE, 2022 In the backdrop of rapidly changing relapsed/refractory (RR) multiple myeloma (MM) treatment schema that mainly evolves around immunotherapies, it is easy to disregard more traditional drugs.
Hyunkyung Park +7 more
doaj +1 more source
Haematologica, 2016 Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure.
Katja C. Weisel +22 more
doaj +1 more source
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
Pathology and Oncology Research, 2022 Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting.
Szilvia Lovas +10 more
doaj +1 more source
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
Communications Biology, 2021 Shimizu et al. identify PLZF/ZBTB16 and its fusion proteins as pomalidomide-dependent neosubstrates of the cereblon E3 ligase. The authors also report that pomalidomide induces their degradation and thereby exerts its anti-cancer effect in leukemic cells
Nobuyuki Shimizu +5 more
doaj +1 more source
Клиническая онкогематология, 2018 The present review includes data on efficacy and safety of pomalidomide, an immunomodulating 3rd generation drug used for treatment of relapsed and refractory multiple myeloma patients with renal failure.
Irina Germanovna Rekhtina +2 more
doaj +1 more source
Pomalidomide-induced hypothyroidism
Endocrinology, Diabetes & Metabolism Case Reports, 2017 Hypothyroidism is a recognized side effect of thalidomide drugs. We herein report a case of 83-year-old Irish female with a diagnosis of multiple myeloma and a background history of type 2 diabetes mellitus and hypertension.
Sulaiman Haji Ali +3 more
doaj +1 more source
Pomalidomide-based therapy for extramedullary multiple myeloma
Hematology, 2022 Objectives Extramedullary disease (EMD) is characterized by plasma cells outside of bone marrow in multiple myeloma (MM) patients, which results in an adverse prognosis. EMD treatment is yet challenging even in the era of novel drugs.
Yating Li +4 more
doaj +1 more source
3,6′- and 1,6′-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation
Pharmaceutics, 2022 (1) Background: An important concomitant of stroke is neuroinflammation. Pomalidomide, a clinically available immunomodulatory imide drug (IMiD) used in cancer therapy, lowers TNF-α generation and thus has potent anti-inflammatory actions. Well-tolerated
Yan-Rou Tsai +18 more
doaj +1 more source